TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup

David P. Labbé, Christopher J. Sweeney, Myles Brown, Phillip Galbo, Spencer Rosario, Kristine M. Wadosky, Sheng Yu Ku, Martin Sjöström, Mohammed Alshalalfa, Nicholas Erho, Elai Davicioni, Robert Jeffrey Karnes, Edward M. Schaeffer, Robert Brian Jenkins, Robert B. Den, Ashley E. Ross, Michaela Bowden, Ying Huang, Kathryn P. Gray, Felix Y. FengDaniel E. Spratt, David W. Goodrich, Kevin H. Eng, Leigh Ellis

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: Current clinical parameters do not stratify indolent from aggressive prostate cancer. Aggressive prostate cancer, defined by the progression from localized disease to metastasis, is responsible for the majority of prostate cancer–associated mortality. Recent gene expression profiling has proven successful in predicting the outcome of prostate cancer patients; however, they have yet to provide targeted therapy approaches that could inhibit a patient's progression to metastatic disease. Experimental Design: We have interrogated a total of seven primary prostate cancer cohorts (n = 1,900), two metastatic castration-resistant prostate cancer datasets (n = 293), and one prospective cohort (n = 1,385) to assess the impact of TOP2A and EZH2 expression on prostate cancer cellular program and patient outcomes. We also performed IHC staining for TOP2A and EZH2 in a cohort of primary prostate cancer patients (n = 89) with known outcome. Finally, we explored the therapeutic potential of a combination therapy targeting both TOP2A and EZH2 using novel prostate cancer–derived murine cell lines. Results: We demonstrate by genome-wide analysis of independent primary and metastatic prostate cancer datasets that concurrent TOP2A and EZH2 mRNA and protein upregulation selected for a subgroup of primary and metastatic patients with more aggressive disease and notable overlap of genes involved in mitotic regulation. Importantly, TOP2A and EZH2 in prostate cancer cells act as key driving oncogenes, a fact highlighted by sensitivity to combination-targeted therapy. Conclusions: Overall, our data support further assessment of TOP2A and EZH2 as biomarkers for early identification of patients with increased metastatic potential that may benefit from adjuvant or neoadjuvant targeted therapy approaches.

Original languageEnglish (US)
Pages (from-to)7072-7083
Number of pages12
JournalClinical Cancer Research
Volume23
Issue number22
DOIs
StatePublished - Nov 15 2017

Fingerprint

Prostatic Neoplasms
Prostate
Neoadjuvant Therapy
Castration
Gene Expression Profiling
Therapeutics
Oncogenes
Disease Progression
Research Design
Up-Regulation
Biomarkers
Genome
Staining and Labeling
Neoplasm Metastasis
Cell Line
Messenger RNA
Mortality
Genes
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Labbé, D. P., Sweeney, C. J., Brown, M., Galbo, P., Rosario, S., Wadosky, K. M., ... Ellis, L. (2017). TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clinical Cancer Research, 23(22), 7072-7083. https://doi.org/10.1158/1078-0432.CCR-17-0413

TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. / Labbé, David P.; Sweeney, Christopher J.; Brown, Myles; Galbo, Phillip; Rosario, Spencer; Wadosky, Kristine M.; Ku, Sheng Yu; Sjöström, Martin; Alshalalfa, Mohammed; Erho, Nicholas; Davicioni, Elai; Karnes, Robert Jeffrey; Schaeffer, Edward M.; Jenkins, Robert Brian; Den, Robert B.; Ross, Ashley E.; Bowden, Michaela; Huang, Ying; Gray, Kathryn P.; Feng, Felix Y.; Spratt, Daniel E.; Goodrich, David W.; Eng, Kevin H.; Ellis, Leigh.

In: Clinical Cancer Research, Vol. 23, No. 22, 15.11.2017, p. 7072-7083.

Research output: Contribution to journalArticle

Labbé, DP, Sweeney, CJ, Brown, M, Galbo, P, Rosario, S, Wadosky, KM, Ku, SY, Sjöström, M, Alshalalfa, M, Erho, N, Davicioni, E, Karnes, RJ, Schaeffer, EM, Jenkins, RB, Den, RB, Ross, AE, Bowden, M, Huang, Y, Gray, KP, Feng, FY, Spratt, DE, Goodrich, DW, Eng, KH & Ellis, L 2017, 'TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup', Clinical Cancer Research, vol. 23, no. 22, pp. 7072-7083. https://doi.org/10.1158/1078-0432.CCR-17-0413
Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM et al. TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clinical Cancer Research. 2017 Nov 15;23(22):7072-7083. https://doi.org/10.1158/1078-0432.CCR-17-0413
Labbé, David P. ; Sweeney, Christopher J. ; Brown, Myles ; Galbo, Phillip ; Rosario, Spencer ; Wadosky, Kristine M. ; Ku, Sheng Yu ; Sjöström, Martin ; Alshalalfa, Mohammed ; Erho, Nicholas ; Davicioni, Elai ; Karnes, Robert Jeffrey ; Schaeffer, Edward M. ; Jenkins, Robert Brian ; Den, Robert B. ; Ross, Ashley E. ; Bowden, Michaela ; Huang, Ying ; Gray, Kathryn P. ; Feng, Felix Y. ; Spratt, Daniel E. ; Goodrich, David W. ; Eng, Kevin H. ; Ellis, Leigh. / TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. In: Clinical Cancer Research. 2017 ; Vol. 23, No. 22. pp. 7072-7083.
@article{f863144ca6f24ac58787bfab8c9ce15e,
title = "TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup",
abstract = "Purpose: Current clinical parameters do not stratify indolent from aggressive prostate cancer. Aggressive prostate cancer, defined by the progression from localized disease to metastasis, is responsible for the majority of prostate cancer–associated mortality. Recent gene expression profiling has proven successful in predicting the outcome of prostate cancer patients; however, they have yet to provide targeted therapy approaches that could inhibit a patient's progression to metastatic disease. Experimental Design: We have interrogated a total of seven primary prostate cancer cohorts (n = 1,900), two metastatic castration-resistant prostate cancer datasets (n = 293), and one prospective cohort (n = 1,385) to assess the impact of TOP2A and EZH2 expression on prostate cancer cellular program and patient outcomes. We also performed IHC staining for TOP2A and EZH2 in a cohort of primary prostate cancer patients (n = 89) with known outcome. Finally, we explored the therapeutic potential of a combination therapy targeting both TOP2A and EZH2 using novel prostate cancer–derived murine cell lines. Results: We demonstrate by genome-wide analysis of independent primary and metastatic prostate cancer datasets that concurrent TOP2A and EZH2 mRNA and protein upregulation selected for a subgroup of primary and metastatic patients with more aggressive disease and notable overlap of genes involved in mitotic regulation. Importantly, TOP2A and EZH2 in prostate cancer cells act as key driving oncogenes, a fact highlighted by sensitivity to combination-targeted therapy. Conclusions: Overall, our data support further assessment of TOP2A and EZH2 as biomarkers for early identification of patients with increased metastatic potential that may benefit from adjuvant or neoadjuvant targeted therapy approaches.",
author = "Labb{\'e}, {David P.} and Sweeney, {Christopher J.} and Myles Brown and Phillip Galbo and Spencer Rosario and Wadosky, {Kristine M.} and Ku, {Sheng Yu} and Martin Sj{\"o}str{\"o}m and Mohammed Alshalalfa and Nicholas Erho and Elai Davicioni and Karnes, {Robert Jeffrey} and Schaeffer, {Edward M.} and Jenkins, {Robert Brian} and Den, {Robert B.} and Ross, {Ashley E.} and Michaela Bowden and Ying Huang and Gray, {Kathryn P.} and Feng, {Felix Y.} and Spratt, {Daniel E.} and Goodrich, {David W.} and Eng, {Kevin H.} and Leigh Ellis",
year = "2017",
month = "11",
day = "15",
doi = "10.1158/1078-0432.CCR-17-0413",
language = "English (US)",
volume = "23",
pages = "7072--7083",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup

AU - Labbé, David P.

AU - Sweeney, Christopher J.

AU - Brown, Myles

AU - Galbo, Phillip

AU - Rosario, Spencer

AU - Wadosky, Kristine M.

AU - Ku, Sheng Yu

AU - Sjöström, Martin

AU - Alshalalfa, Mohammed

AU - Erho, Nicholas

AU - Davicioni, Elai

AU - Karnes, Robert Jeffrey

AU - Schaeffer, Edward M.

AU - Jenkins, Robert Brian

AU - Den, Robert B.

AU - Ross, Ashley E.

AU - Bowden, Michaela

AU - Huang, Ying

AU - Gray, Kathryn P.

AU - Feng, Felix Y.

AU - Spratt, Daniel E.

AU - Goodrich, David W.

AU - Eng, Kevin H.

AU - Ellis, Leigh

PY - 2017/11/15

Y1 - 2017/11/15

N2 - Purpose: Current clinical parameters do not stratify indolent from aggressive prostate cancer. Aggressive prostate cancer, defined by the progression from localized disease to metastasis, is responsible for the majority of prostate cancer–associated mortality. Recent gene expression profiling has proven successful in predicting the outcome of prostate cancer patients; however, they have yet to provide targeted therapy approaches that could inhibit a patient's progression to metastatic disease. Experimental Design: We have interrogated a total of seven primary prostate cancer cohorts (n = 1,900), two metastatic castration-resistant prostate cancer datasets (n = 293), and one prospective cohort (n = 1,385) to assess the impact of TOP2A and EZH2 expression on prostate cancer cellular program and patient outcomes. We also performed IHC staining for TOP2A and EZH2 in a cohort of primary prostate cancer patients (n = 89) with known outcome. Finally, we explored the therapeutic potential of a combination therapy targeting both TOP2A and EZH2 using novel prostate cancer–derived murine cell lines. Results: We demonstrate by genome-wide analysis of independent primary and metastatic prostate cancer datasets that concurrent TOP2A and EZH2 mRNA and protein upregulation selected for a subgroup of primary and metastatic patients with more aggressive disease and notable overlap of genes involved in mitotic regulation. Importantly, TOP2A and EZH2 in prostate cancer cells act as key driving oncogenes, a fact highlighted by sensitivity to combination-targeted therapy. Conclusions: Overall, our data support further assessment of TOP2A and EZH2 as biomarkers for early identification of patients with increased metastatic potential that may benefit from adjuvant or neoadjuvant targeted therapy approaches.

AB - Purpose: Current clinical parameters do not stratify indolent from aggressive prostate cancer. Aggressive prostate cancer, defined by the progression from localized disease to metastasis, is responsible for the majority of prostate cancer–associated mortality. Recent gene expression profiling has proven successful in predicting the outcome of prostate cancer patients; however, they have yet to provide targeted therapy approaches that could inhibit a patient's progression to metastatic disease. Experimental Design: We have interrogated a total of seven primary prostate cancer cohorts (n = 1,900), two metastatic castration-resistant prostate cancer datasets (n = 293), and one prospective cohort (n = 1,385) to assess the impact of TOP2A and EZH2 expression on prostate cancer cellular program and patient outcomes. We also performed IHC staining for TOP2A and EZH2 in a cohort of primary prostate cancer patients (n = 89) with known outcome. Finally, we explored the therapeutic potential of a combination therapy targeting both TOP2A and EZH2 using novel prostate cancer–derived murine cell lines. Results: We demonstrate by genome-wide analysis of independent primary and metastatic prostate cancer datasets that concurrent TOP2A and EZH2 mRNA and protein upregulation selected for a subgroup of primary and metastatic patients with more aggressive disease and notable overlap of genes involved in mitotic regulation. Importantly, TOP2A and EZH2 in prostate cancer cells act as key driving oncogenes, a fact highlighted by sensitivity to combination-targeted therapy. Conclusions: Overall, our data support further assessment of TOP2A and EZH2 as biomarkers for early identification of patients with increased metastatic potential that may benefit from adjuvant or neoadjuvant targeted therapy approaches.

UR - http://www.scopus.com/inward/record.url?scp=85034843446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034843446&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-17-0413

DO - 10.1158/1078-0432.CCR-17-0413

M3 - Article

C2 - 28899973

AN - SCOPUS:85034843446

VL - 23

SP - 7072

EP - 7083

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 22

ER -